{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:08:04Z","timestamp":1767337684293},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>Marfan Syndrome (MFS) is an autosomal dominant, genetically inherited connective tissue disorder which primarily affects the cardiovascular system, but can also have systemic manifestations. First described in 1896, MFS has a prevalence of around 1\/5000 in the general population. It is becoming increasingly common to see patients with MFS in a clinical setting due to the improved care of patients with adult congenital heart disease and general improvement in survival. Mortality, however, remains high largely due to the risk of aortic dissection as a result of the aortic root dilatation frequently seen in these patients. Contemporary management has therefore been focused on imaging-based surveillance to prevent these catastrophic events and intervene surgically in a timely manner. However, it is increasingly recognized that some patients do suffer aortic dissection below the expected threshold for surgical intervention. With this in mind, there has been interest in the role of biomarkers as an adjunct to imaging in the care of these patients. This article will provide an overview of the literature on potential biomarkers studied so far in MFS, as well as potential future directions.<\/jats:p>","DOI":"10.1097\/crd.0000000000000289","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T13:44:28Z","timestamp":1580132668000},"page":"92-97","source":"Crossref","is-referenced-by-count":11,"title":["Biomarkers of Aortopathy in Marfan Syndrome"],"prefix":"10.1097","volume":"28","author":[{"given":"Zaid","family":"Iskandar","sequence":"first","affiliation":[{"name":"Department of Molecular & Clinical Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ify","family":"Mordi","sequence":"additional","affiliation":[{"name":"Department of Molecular & Clinical Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chim C.","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Molecular & Clinical Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T. J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Biomarker and Drug Analysis Core Facility, Medical Research Institute, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Maria","family":"Choy","sequence":"additional","affiliation":[{"name":"Department of Molecular & Clinical Medicine, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13023-015-0369-8","article-title":"Prevalence, incidence, and age at diagnosis in Marfan syndrome.","volume":"10","author":"Groth","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/TACG.S96233","article-title":"Marfan syndrome: current perspectives.","volume":"9","author":"Pepe","year":"2016","journal-title":"Appl Clin Genet"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/352337a0","article-title":"Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.","volume":"352","author":"Dietz","year":"1991","journal-title":"Nature"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJM199904293401702","article-title":"Replacement of the aortic root in patients with Marfan\u2019s syndrome.","volume":"340","author":"Gott","year":"1999","journal-title":"N Engl J Med"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1093\/eurheartj\/ehq249","article-title":"ESC Guidelines for the management of grown-up congenital heart disease (new version 2010).","volume":"31","author":"Baumgartner","year":"2010","journal-title":"Eur Heart J"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0002-9149(00)80066-1","article-title":"Life expectancy in the Marfan syndrome.","volume":"75","author":"Silverman","year":"1995","journal-title":"Am J Cardiol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng1116","article-title":"Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.","volume":"33","author":"Neptune","year":"2003","journal-title":"Nat Genet"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/sj.ejhg.5201851","article-title":"Marfan syndrome: clinical diagnosis and management.","volume":"15","author":"Dean","year":"2007","journal-title":"Eur J Hum Genet"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Atenolol versus losartan in children and young adults with Marfan\u2019s syndrome.","volume":"371","author":"Lacro","year":"2014","journal-title":"N Engl J Med"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ahj.2015.01.011","article-title":"Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan Treatment Trialists\u2019 Collaboration.","volume":"169","author":"Pitcher","year":"2015","journal-title":"Am Heart J"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial.","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur Heart J"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/1745-6215-14-408","article-title":"A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol.","volume":"14","author":"Mullen","year":"2013","journal-title":"Trials"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","article-title":"Marfan Sartan: a randomized, double-blind, placebo-controlled trial.","volume":"36","author":"Milleron","year":"2015","journal-title":"Eur Heart J"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan\u2019s syndrome.","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"894308","DOI":"10.1155\/2012\/894308","article-title":"Appreciating the strengths and weaknesses of transthoracic echocardiography in hemodynamic assessments.","volume":"2012","author":"Huang","year":"2012","journal-title":"Cardiol Res Pract"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1161\/CIRCULATIONAHA.107.702720","article-title":"Aortic diameter >or = 5.5\u2009cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD).","volume":"116","author":"Pape","year":"2007","journal-title":"Circulation"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/ajh.2010.78","article-title":"Augmentation index and the evolution of aortic disease in marfan-like syndromes.","volume":"23","author":"Mortensen","year":"2010","journal-title":"Am J Hypertens"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/ajh.2009.115","article-title":"Augmentation index relates to progression of aortic disease in adults with Marfan syndrome.","volume":"22","author":"Mortensen","year":"2009","journal-title":"Am J Hypertens"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1749-8090-2-43","article-title":"Augmentation index assessed by applanation tonometry is elevated in Marfan Syndrome.","volume":"2","author":"Payne","year":"2007","journal-title":"J Cardiothorac Surg"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ijcard.2013.03.033","article-title":"Circulating transforming growth factor-\u03b2 as a prognostic biomarker in Marfan syndrome.","volume":"168","author":"Franken","year":"2013","journal-title":"Int J Cardiol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/clc.22320","article-title":"Total serum transforming growth factor-\u03b21 is elevated in the entire spectrum of genetic aortic syndromes.","volume":"37","author":"Hillebrand","year":"2014","journal-title":"Clin Cardiol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCULATIONAHA.108.841981","article-title":"Circulating transforming growth factor-beta in Marfan syndrome.","volume":"120","author":"Matt","year":"2009","journal-title":"Circulation"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s12471-014-0622-0","article-title":"The revised role of TGF-\u03b2 in aortic aneurysms in Marfan syndrome.","volume":"23","author":"Franken","year":"2015","journal-title":"Neth Heart J"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"e32963","DOI":"10.1371\/journal.pone.0032963","article-title":"Inflammation aggravates disease severity in Marfan syndrome patients.","volume":"7","author":"Radonic","year":"2012","journal-title":"PLoS One"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1536\/ihj.54.23","article-title":"Circulating transforming growth factor \u03b2-1 level in Japanese patients with Marfan syndrome.","volume":"54","author":"Ogawa","year":"2013","journal-title":"Int Heart J"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1253\/circj.CJ-12-0874","article-title":"Positive correlation between the dysregulation of transforming growth factor-\u03b21 and aneurysmal pathological changes in patients with Marfan syndrome.","volume":"77","author":"Kim","year":"2013","journal-title":"Circ J"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.113.301498","article-title":"Thoracic aortic aneurysm frequency and dissection are associated with fibrillin-1 fragment concentrations in circulation.","volume":"113","author":"Marshall","year":"2013","journal-title":"Circ Res"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.ehj.2003.08.020","article-title":"Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism.","volume":"24","author":"Giusti","year":"2003","journal-title":"Eur Heart J"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/hrt.2006.109454","article-title":"Medical treatment of Marfan syndrome: a time for change.","volume":"94","author":"Williams","year":"2008","journal-title":"Heart"},{"issue":"1 suppl","key":"R32-20230903","first-page":"I365","article-title":"Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome.","volume":"114","author":"Ikonomidis","year":"2006","journal-title":"Circulation"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2459\/JCM.0b013e3283588dfa","article-title":"Nonstenotic bicuspid aortic valve is associated with elevated plasma asymmetric dimethylarginine.","volume":"14","author":"Drapisz","year":"2013","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00380-014-0593-5","article-title":"Circulating matrix metalloproteinase patterns in association with aortic dilatation in bicuspid aortic valve patients with isolated severe aortic stenosis.","volume":"31","author":"Wang","year":"2016","journal-title":"Heart Vessels"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jss.2004.06.007","article-title":"Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves.","volume":"123","author":"LeMaire","year":"2005","journal-title":"J Surg Res"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jacc.2009.08.080","article-title":"Endothelial function, carotid-femoral stiffness, and plasma matrix metalloproteinase-2 in men with bicuspid aortic valve and dilated aorta.","volume":"55","author":"Tzemos","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jtcvs.2012.12.027","article-title":"Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease.","volume":"145","author":"Ikonomidis","year":"2013","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R38-20230903","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jtcvs.2003.11.049","article-title":"Matrix metalloproteinase activity in thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves.","volume":"127","author":"Boyum","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R39-20230903","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1161\/01.CIR.0000038109.84500.1E","article-title":"Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice.","volume":"106","author":"Joni","year":"2002","journal-title":"Circulation"},{"key":"R40-20230903","doi-asserted-by":"crossref","first-page":"H1067","DOI":"10.1152\/ajpheart.00217.2012","article-title":"The role of lysyl oxidase family members in the stabilization of abdominal aortic aneurysms.","volume":"303","author":"Remus","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R41-20230903","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0741-5214(95)70110-9","article-title":"Increased turnover of collagen in abdominal aortic aneurysms, demonstrated by measuring the concentration of the aminoterminal propeptide of type III procollagen in peripheral and aortal blood samples.","volume":"22","author":"Satta","year":"1995","journal-title":"J Vasc Surg"},{"key":"R42-20230903","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/ejvs.2001.1303","article-title":"The relationship between abdominal aortic aneurysm distensibility and serum markers of elastin and collagen metabolism.","volume":"21","author":"Wilson","year":"2001","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R43-20230903","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/humu.10249","article-title":"Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database.","volume":"22","author":"Collod-B\u00e9roud","year":"2003","journal-title":"Hum Mutat"},{"key":"R44-20230903","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0002-8703(97)70148-0","article-title":"Correlation between plasma homocyst(e)ine and aortic atherosclerosis.","volume":"133","author":"Konecky","year":"1997","journal-title":"Am Heart J"},{"key":"R45-20230903","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1006\/bbrc.1999.1391","article-title":"Influence of homocysteine on matrix metalloproteinase-2: activation and activity.","volume":"263","author":"Bescond","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"R46-20230903","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0008-6363(97)00048-5","article-title":"Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors.","volume":"34","author":"Jourdheuil-Rahmani","year":"1997","journal-title":"Cardiovasc Res"},{"issue":"19 suppl","key":"R47-20230903","first-page":"II331","article-title":"Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan\u2019s syndrome.","volume":"98","author":"Segura","year":"1998","journal-title":"Circulation"},{"key":"R48-20230903","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1161\/CIRCRESAHA.112.268268","article-title":"MMP-2 regulates Erk1\/2 phosphorylation and aortic dilatation in Marfan syndrome.","volume":"110","author":"Xiong","year":"2012","journal-title":"Circ Res"},{"key":"R49-20230903","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCRESAHA.107.157776","article-title":"Loss of elastic fiber integrity and reduction of vascular smooth muscle contraction resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in the thoracic aortic aneurysm in Marfan syndrome.","volume":"101","author":"Chung","year":"2007","journal-title":"Circ Res"},{"key":"R50-20230903","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0022-5223(03)00398-2","article-title":"Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation.","volume":"126","author":"Fedak","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R51-20230903","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3389\/fphys.2017.00429","article-title":"Non-coding RNA contribution to thoracic and abdominal aortic aneurysm disease development and progression.","volume":"8","author":"Li","year":"2017","journal-title":"Front Physiol"},{"key":"R52-20230903","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.110.990549","article-title":"Increased vertebral artery tortuosity index is associated with adverse outcomes in children and young adults with connective tissue disorders.","volume":"124","author":"Morris","year":"2011","journal-title":"Circulation"},{"key":"R53-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2015.05.072","article-title":"Increased aortic tortuosity indicates a more severe aortic phenotype in adults with Marfan syndrome.","volume":"194","author":"Franken","year":"2015","journal-title":"Int J Cardiol"},{"issue":"suppl_1","key":"R54-20230903","doi-asserted-by":"crossref","first-page":"ehy566.P6040","DOI":"10.1093\/eurheartj\/ehy566.P6040","article-title":"The novel biomarker plasma desmosine, a marker of elastin breakdown, is an independent predictor of abdominal aortic aneurysm events independent of aneurysm size.","volume":"39","author":"Mordi","year":"2018","journal-title":"Eur Heart J"},{"issue":"suppl 6","key":"R55-20230903","first-page":"A103","article-title":"126 Urinary desmosine, a biomarker of elastin degradation is significantly elevated and associated with maximum aortic root size and aortic Z-scores in patients with bicuspid aortic valve.","volume":"105","author":"Iskandar","year":"2019","journal-title":"Heart"},{"issue":"suppl 1","key":"R56-20230903","first-page":"1","article-title":"Desmosine, a circulating biomarker of elastin breakdown in marfan syndrome aortopathy.","volume":"38","author":"McGowan","year":"2017","journal-title":"Eur Heart J"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T09:11:15Z","timestamp":1693732275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000289","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}